Long-term safety of oral orforglipron in Japanese people with type 2 diabetes

Orforglipron, an oral GLP-1 receptor agonist, requires further evaluation in East Asian populations with type 2 diabetes.

• The study focused on Japanese participants with type 2 diabetes.
• Orforglipron may serve as an additional treatment alongside diet and exercise or oral diabetes medications.
• Distinct pathophysiological characteristics in East Asian populations could influence treatment outcomes.

Simplified